Work Here?
Overview
Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.
About Tr1X
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$125M
Headquarters
San Diego, California
Founded
2018
Get referred to Tr1X
See people who can refer or advise you
Simplify's Take
What believers are saying
- CIRM approved $8 million for TRX319 in June 2026, supporting execution.
- October 2025 financing extended runway into 2027, reducing near-term fundraising pressure.
- ASGCT 2026 presentations kept Tr1X visible among autoimmune cell-therapy investors.
What critics are saying
- TRX103 still lacks efficacy proof beyond small Phase 1 cohorts in 2026.
- TRX319's 39-patient trial runs through 2029, delaying commercialization and de-risking.
- If TRX103 and TRX319 fail, Tr1X has no approved products or revenue.
What makes Tr1X unique
- Tr1X pairs allogeneic Tr1 cells with CAR-Tr1 engineering, unlike autologous competitors.
- TRX103 produced early safety, persistence, and immune-reconstitution signals in 2026 HSCT patients.
- TRX319 targets progressive multiple sclerosis with a first-in-class off-the-shelf CAR-Tr1 approach.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$125M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
401(k) Company Match
Flexible Work Hours
Stock Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↓ -2%Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.
Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...
TR1X awarded $8M grant for TRX103 GvHD trial.
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025
Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.
Tr1X is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Tr1X
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$125M
Headquarters
San Diego, California
Founded
2018
Tr1X is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today